SEC Form SC 13G/A filed by Intercept Pharmaceuticals Inc. (Amendment)

10/11/22 9:03:50 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $ICPT alert in real time by email

SC 13G/A 1 filing.txt SCHEDULE 13G Amendment No.11 INTERCEPT PHARMACEUTICALS INC COMMON STOCK Cusip #45845P108 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #45845P108 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 928,682 Item 6: 0 Item 7: 934,378 Item 8: 0 Item 9: 934,378 Item 11: 2.371% Item 12: HC Cusip #45845P108 Item 1: Reporting Person - Abigail P. Johnson Item 2: (a) [ ] (b) [ ] Item 4: United States of America Item 5: 0 Item 6: 0 Item 7: 934,378 Item 8: 0 Item 9: 934,378 Item 11: 2.371% Item 12: IN Item 1(a). Name of Issuer: INTERCEPT PHARMACEUTICALS INC Item 1(b). Address of Issuer's Principal Executive Offices: 305 MADISON AVENUE MORRISTOWN, NJ 07960 USA Item 2(a). Name of Person Filing: FMR LLC Item 2(b). Address or Principal Business Office or, if None, Residence: 245 Summer Street, Boston, Massachusetts 02210 Item 2(c). Citizenship: Not applicable Item 2(d). Title of Class of Securities: COMMON STOCK Item 2(e). CUSIP Number: 45845P108 Item 3. This statement is filed pursuant to Rule 13d-1(b) or 13d-2(b) or (c) and the person filing, FMR LLC, is a parent holding company in accordance with Section 240.13d-1(b)(1)(ii)(G). (Note: See Exhibit A). Item 4. Ownership (a) Amount Beneficially Owned: 934,378 (b) Percent of Class: 2.371% (c) Number of shares as to which such person has: (i) sole power to vote or to direct the vote: Please see the responses to Items 5 and 6 on the cover page (ii) shared power to vote or to direct the vote: 0 (iii) sole power to dispose or to direct the disposition of: 934,378 (iv) shared power to dispose or to direct the disposition of: 0 Item 5. Ownership of Five Percent or Less of a Class. If this statement is being filed to report the fact that as of the date hereof, the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following (X). Item 6. Ownership of More than Five Percent on Behalf of Another Person. One or more other persons are known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the COMMON STOCK of INTERCEPT PHARMACEUTICALS INC. No one other person's interest in the COMMON STOCK of INTERCEPT PHARMACEUTICALS INC is more than five percent of the total outstanding COMMON STOCK. Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company. See attached Exhibit A. Item 8. Identification and Classification of Members of the Group. Not applicable. Item 9. Notice of Dissolution of Group. Not applicable. Item 10. Certifications. By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing orinfluencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. Signature After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. October 7, 2022 Date /s/ Kevin M. Meagher Signature Kevin M. Meagher Duly authorized under Power of Attorney effective as of September 28, 2018, by and on behalf of FMR LLC and its direct and indirect subsidiaries* * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on October 9, 2018, accession number: 0000315066-18-002414. Exhibit A Pursuant to the instructions in Item 7 of Schedule 13G, the following table lists the identity and Item 3 classification, if applicable, of each relevant entity that beneficially owns shares of the security class being reported on this Schedule 13G. Entity ITEM 3 Classification FIAM LLC IA Fidelity Institutional Asset Management Trust Company BK Fidelity Management & Research Company LLC IA Strategic Advisers LLC IA Abigail P. Johnson is a Director, the Chairman and the Chief Executive Officer of FMR LLC. Members of the Johnson family, including Abigail P. Johnson, are the predominant owners, directly or through trusts, of Series B voting common shares of FMR LLC, representing 49% of the voting power of FMR LLC. The Johnson family group and all other Series B shareholders have entered into a shareholders' voting agreement under which all Series B voting common shares will be voted in accordance with the majority vote of Series B voting common shares. Accordingly, through their ownership of voting common shares and the execution of the shareholders' voting agreement, members of the Johnson family may be deemed, under the Investment Company Act of 1940, to form a controlling group with respect to FMR LLC. This filing reflects the securities beneficially owned, or that may be deemed to be beneficially owned, by FMR LLC, certain of its subsidiaries and affiliates, and other companies (collectively, the "FMR Reporters"). This filing does not reflect securities, if any, beneficially owned by certain other companies whose beneficial ownership of securities is disaggregated from that of the FMR Reporters in accordance with Securities and Exchange Commission Release No. 34-39538 (January 12, 1998). RULE 13d-1(k)(1) AGREEMENT The undersigned persons, on October 7, 2022, agree and consent to the joint filing on their behalf of this Schedule 13G in connection with their beneficial ownership of the COMMON STOCK of INTERCEPT PHARMACEUTICALS INC at September 30, 2022. FMR LLC By /s/ Kevin M. Meagher Kevin M. Meagher Duly authorized under Power of Attorney effective as of September 28, 2018, by and on behalf of FMR LLC and its direct and indirect subsidiaries* Abigail P. Johnson By /s/ Kevin M. Meagher Kevin M. Meagher Duly authorized under Power of Attorney effective as of September 30, 2018, by and on behalf of Abigail P. Johnson* * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on October 9, 2018, accession number: 0000315066-18-002414.

Get the next $ICPT alert in real time by email

Recent Analyst Ratings for

$ICPT

Date	Price Target	Rating	Analyst
7/13/2023	$8.00 → $19.00	Sell → Buy	H.C. Wainwright
6/29/2023	$12.00 → $18.00	Hold → Buy	Canaccord Genuity
5/23/2023		Buy → Hold	Needham
5/22/2023	$8.00	Neutral → Sell	H.C. Wainwright
5/17/2023		Outperform → Mkt Perform	Raymond James
3/8/2022	$31.00 → $29.00	Hold	Canaccord Genuity
3/3/2022	$22.00 → $16.00	Sector Perform	RBC Capital
3/3/2022	$30.00 → $25.00	Buy	Needham

More analyst ratings

SEC Form SC 13G/A filed by Intercept Pharmaceuticals Inc. (Amendment)

10/11/22 9:03:50 AM ET

$ICPT

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $ICPT alert in real time by email

Recent Analyst Ratings for

$ICPT

Date	Price Target	Rating	Analyst
7/13/2023	$8.00 → $19.00	Sell → Buy	H.C. Wainwright
6/29/2023	$12.00 → $18.00	Hold → Buy	Canaccord Genuity
5/23/2023		Buy → Hold	Needham
5/22/2023	$8.00	Neutral → Sell	H.C. Wainwright
5/17/2023		Outperform → Mkt Perform	Raymond James
3/8/2022	$31.00 → $29.00	Hold	Canaccord Genuity
3/3/2022	$22.00 → $16.00	Sector Perform	RBC Capital
3/3/2022	$30.00 → $25.00	Buy	Needham

More analyst ratings

SEC Form SC 13G/A filed by Intercept Pharmaceuticals Inc. (Amendment)

Crush Q3 2025 with the Best AI Executive Assistant

Recent Analyst Ratings for $ICPT

SEC Form SC 13G/A filed by Intercept Pharmaceuticals Inc. (Amendment)

Crush Q3 2025 with the Best AI Executive Assistant

Recent Analyst Ratings for $ICPT

$ICPT FDA approvals

Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

FDA Approval for OCALIVA issued to INTERCEPT PHARMS INC

FDA Approval for OCALIVA issued to INTERCEPT PHARMS INC

$ICPT Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Akkaraju Srinivas returned $154,109 worth of shares to the company (8,111 units at $19.00), closing all direct ownership in the company (SEC Form 4)

Fundaro Paolo returned $154,109 worth of shares to the company (8,111 units at $19.00), closing all direct ownership in the company (SEC Form 4)

Venezia Rocco returned $278,711 worth of shares to the company (14,669 units at $19.00), closing all direct ownership in the company (SEC Form 4)

$ICPT SEC Filings

SEC Form 15-12G filed by Intercept Pharmaceuticals Inc.

SEC Form EFFECT filed by Intercept Pharmaceuticals Inc.

SEC Form EFFECT filed by Intercept Pharmaceuticals Inc.

$ICPT Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Intercept Pharma upgraded by H.C. Wainwright with a new price target

Intercept Pharma upgraded by Canaccord Genuity with a new price target

Intercept Pharma downgraded by Needham

$ICPT Press Releases

Fastest customizable press release news feed in the world

Intercept Announces New PBC Data Analyses to be Presented at Digestive Disease Week® 2024 Conference

Intercept Announces FDA Acceptance of Supplemental New Drug Application for Ocaliva® (obeticholic acid) for the Treatment of PBC

Alfasigma completes acquisition of Intercept Pharmaceuticals, Inc.

$ICPT Leadership Updates

Live Leadership Updates

Persephone Biosciences Appoints Daniel Bradbury as Chair of the Board of Directors

Intercept Appoints M. Michelle Berrey, M.D., M.P.H., as President of Research & Development and Chief Medical Officer

Intercept Appoints Dagmar Rosa-Bjorkeson to Its Board of Directors

$ICPT Financials

Live finance-specific insights

Intercept to Announce Second Quarter 2023 Financial Results on August 2, 2023

Intercept Receives Complete Response Letter from FDA for Obeticholic Acid as a Treatment for Pre-Cirrhotic Fibrosis due to NASH

Intercept Announces Outcome of FDA Advisory Committee Meeting for Obeticholic Acid as a Treatment for Pre-Cirrhotic Fibrosis due to NASH

$ICPT Large Ownership Changes

This live feed shows all institutional transactions in real time.